Indeed, A2AR role in causing tumor immune suppression in hypoxic tumors is a consolidated notion that recently lead to several clinical trials exploring the anti-cancer therapeutic efficacy of the administration of A2AR antagonists as a stand-alone treatment or in combination with immune checkpoints inhibitors (Boison and Yegutkin, 2019; Fong et al., 2020; Franco et al., 2021; Augustin et al., 2022). Here, ADORA2A is linked to cancer.